Ascelia Pharma AB (ACE) Stock Statistics & Valuation Metrics

Ascelia Pharma AB has a market cap or net worth of kr386.32M. The enterprise value is kr324.18M.

Ascelia Pharma AB has 126,868,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascelia Pharma AB’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -73.35%.

The current PE Ratio of Ascelia Pharma AB is ―. Ascelia Pharma AB’s PEG ratio is 0.09.

In the last 12 months, Ascelia Pharma AB had revenue of 0.00 and earned -76.25M in profits. Earnings per share was -0.67.

In the last 12 months, operating cash flow was -55.35M and capital expenditures -57.00K, giving a free cash flow of -55.41M billion.

Ascelia Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Ascelia Pharma AB upcoming earnings date is May 14, 2026, Before Open (Confirmed).

Ascelia Pharma AB as a current ratio of 4.35, with Debt / Equity ratio of 1.05%

In the past 12 months, Ascelia Pharma AB has paid -468.00K in taxes.

Ascelia Pharma AB EV to EBITDA ratio is -4.44, with an EV/FCF ratio of -4.38.

Ascelia Pharma AB has kr49.86M in cash and marketable securities with kr1.04M in debt, giving a net cash position of kr48.82M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Ascelia Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―